Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY HACHIGIAN

Allopathic & Osteopathic Physicians Emergency Medicine

NPI
1558342022
CMS profile
777601
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$108.33

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $108.33 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY HACHIGIAN

NPI 1558342022 · CMS profile ID 777601

Allopathic & Osteopathic Physicians / Emergency Medicine

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $108.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka Pharmaceutical Development & Commercialization, Inc. $108.3307/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933756527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $108.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $281,766.82 21
PY2023 Principal investigator $1,564,117.66 137
PY2022 Principal investigator $4,578,170.79 303
PY2021 Principal investigator $4,478,036.63 220
PY2020 Principal investigator $6,027.12 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

303 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $1,505.70 12/23/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493083
Principal investigator 1 ModernaTX, Inc. $450.00 12/23/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493087
Principal investigator 1 ModernaTX, Inc. $1,248.75 12/23/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493117
Principal investigator 1 ModernaTX, Inc. $42,755.00 12/23/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493231
Principal investigator 1 ModernaTX, Inc. $499.85 12/21/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492905
Principal investigator 1 ModernaTX, Inc. $1,275.00 12/21/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492909
Principal investigator 1 ModernaTX, Inc. $650.00 12/21/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492925
Principal investigator 1 ModernaTX, Inc. $1,999.40 12/16/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492893
Principal investigator 1 ModernaTX, Inc. $75.00 12/16/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492897
Principal investigator 1 ModernaTX, Inc. $2,246.63 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963492991
Principal investigator 1 ModernaTX, Inc. $65,387.32 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493007
Principal investigator 1 ModernaTX, Inc. $157,867.88 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493037
Principal investigator 1 ModernaTX, Inc. $323,064.12 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493041
Principal investigator 1 ModernaTX, Inc. $59,187.50 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493177
Principal investigator 1 ModernaTX, Inc. $101,553.75 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493181
Principal investigator 1 ModernaTX, Inc. $8,336.25 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963493187
Principal investigator 1 ModernaTX, Inc. $88.13 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963493687
Principal investigator 1 ModernaTX, Inc. $13,408.27 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963493693
Principal investigator 1 ModernaTX, Inc. $3,265.00 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963493697
Principal investigator 1 ModernaTX, Inc. $18,900.00 12/14/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963493703
Principal investigator 1 ModernaTX, Inc. $8,872.88 12/09/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963492947
Principal investigator 1 ModernaTX, Inc. $13,712.63 12/09/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963492953
Principal investigator 1 ModernaTX, Inc. $793.13 12/09/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963493681
Principal investigator 1 ModernaTX, Inc. $31,531.50 12/02/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492743
Principal investigator 1 ModernaTX, Inc. $14,731.60 12/02/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492749
Principal investigator 1 ModernaTX, Inc. $3,139.50 12/02/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492773
Principal investigator 1 ModernaTX, Inc. $1,999.40 12/02/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963492803
Principal investigator 1 ModernaTX, Inc. $2,706.75 12/01/2022 Non-covered Recipient Entity
Benchmark Research
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963492929
Principal investigator 1 ModernaTX, Inc. $6,063.75 11/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479393
Principal investigator 1 ModernaTX, Inc. $210.00 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478891
Principal investigator 1 ModernaTX, Inc. $3,400.00 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478915
Principal investigator 1 ModernaTX, Inc. $16,391.63 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478985
Principal investigator 1 ModernaTX, Inc. $35,263.13 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478995
Principal investigator 1 ModernaTX, Inc. $900.00 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479001
Principal investigator 1 ModernaTX, Inc. $821.25 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479005
Principal investigator 1 ModernaTX, Inc. $2,497.50 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479011
Principal investigator 1 ModernaTX, Inc. $540.00 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479015
Principal investigator 1 ModernaTX, Inc. $112,133.75 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479041
Principal investigator 1 ModernaTX, Inc. $19,976.25 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479045
Principal investigator 1 ModernaTX, Inc. $28,042.50 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479389
Principal investigator 1 ModernaTX, Inc. $32.50 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479403
Principal investigator 1 ModernaTX, Inc. $21,257.50 11/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963479407
Principal investigator 1 Janssen Research & Development, LLC $6,231.00 11/18/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236235
Principal investigator 1 ModernaTX, Inc. $28,877.55 11/18/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478861
Principal investigator 1 ModernaTX, Inc. $4,574.70 11/18/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478867
Principal investigator 1 ModernaTX, Inc. $6,314.10 11/18/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478871
Principal investigator 1 Janssen Research & Development, LLC $16,530.00 11/16/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236239
Principal investigator 1 ModernaTX, Inc. $11,142.18 11/14/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478945
Principal investigator 1 ModernaTX, Inc. $5,520.90 11/14/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478949
Principal investigator 1 ModernaTX, Inc. $75.00 11/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478919
Principal investigator 1 ModernaTX, Inc. $5,895.00 11/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478955
Principal investigator 1 ModernaTX, Inc. $2,310.00 11/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478959
Principal investigator 1 ModernaTX, Inc. $675.00 11/02/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963479421
Principal investigator 1 ModernaTX, Inc. $2,950.00 11/02/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963479427
Principal investigator 1 ModernaTX, Inc. $1,590.00 11/02/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963479431
Principal investigator 1 Janssen Research & Development, LLC $3,548.00 10/21/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236229
Principal investigator 1 ModernaTX, Inc. $2,110.00 10/21/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478659
Principal investigator 1 ModernaTX, Inc. $821.25 10/21/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478719
Principal investigator 1 Janssen Research & Development, LLC $64,390.00 10/19/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236231
Principal investigator 1 ModernaTX, Inc. $30,728.10 10/19/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478643
Principal investigator 1 ModernaTX, Inc. $239,845.45 10/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963478609
Principal investigator 1 ModernaTX, Inc. $19,837.13 10/05/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478683
Principal investigator 1 ModernaTX, Inc. $821.25 10/05/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478693
Principal investigator 1 ModernaTX, Inc. $351.00 09/28/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475081
Principal investigator 1 Janssen Research & Development, LLC $2,535.00 09/26/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236153
Principal investigator 1 ModernaTX, Inc. $821.25 09/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476389
Principal investigator 1 ModernaTX, Inc. $821.25 09/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476393
Principal investigator 1 ModernaTX, Inc. $13,072.80 09/21/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475299
Principal investigator 1 Janssen Research & Development, LLC $10,401.00 09/19/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236157
Principal investigator 1 ModernaTX, Inc. $42,849.30 09/07/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475511
Principal investigator 1 ModernaTX, Inc. $7,932.60 08/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475227
Principal investigator 1 ModernaTX, Inc. $8,073.00 08/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475247
Principal investigator 1 ModernaTX, Inc. $76,982.75 08/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475597
Principal investigator 1 ModernaTX, Inc. $3,105.00 08/26/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477089
Principal investigator 1 ModernaTX, Inc. $821.25 08/24/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476379
Principal investigator 1 ModernaTX, Inc. $2,587.50 08/22/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477003
Principal investigator 1 ModernaTX, Inc. $6,795.00 08/22/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477597
Principal investigator 1 ModernaTX, Inc. $11,342.94 08/22/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477919
Principal investigator 1 ModernaTX, Inc. $8,424.00 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475251
Principal investigator 1 ModernaTX, Inc. $12,480.00 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475295
Principal investigator 1 ModernaTX, Inc. $17,218.50 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475315
Principal investigator 1 ModernaTX, Inc. $21,333.00 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475349
Principal investigator 1 ModernaTX, Inc. $21,516.30 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475353
Principal investigator 1 ModernaTX, Inc. $22,698.00 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475393
Principal investigator 1 ModernaTX, Inc. $24,035.70 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475399
Principal investigator 1 ModernaTX, Inc. $26,562.90 08/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475409
Principal investigator 1 ModernaTX, Inc. $22,530.38 08/15/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478119
Principal investigator 1 ModernaTX, Inc. $1,800.00 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475131
Principal investigator 1 ModernaTX, Inc. $821.25 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476375
Principal investigator 1 ModernaTX, Inc. $4,927.50 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477383
Principal investigator 1 ModernaTX, Inc. $6,165.00 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477503
Principal investigator 1 ModernaTX, Inc. $7,391.25 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477689
Principal investigator 1 ModernaTX, Inc. $11,443.32 08/12/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477923
Principal investigator 1 ModernaTX, Inc. $19,710.00 08/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478099
Principal investigator 1 Janssen Research & Development, LLC $816.00 08/03/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236149
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/01/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476699
Principal investigator 1 ModernaTX, Inc. $1,800.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475121
Principal investigator 1 ModernaTX, Inc. $5,300.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475201
Principal investigator 1 ModernaTX, Inc. $8,000.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475235
Principal investigator 1 ModernaTX, Inc. $1,891.50 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475697
Principal investigator 1 ModernaTX, Inc. $48,839.70 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475701
Principal investigator 1 ModernaTX, Inc. $60,829.60 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475707
Principal investigator 1 ModernaTX, Inc. $360.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476081
Principal investigator 1 ModernaTX, Inc. $1,093.50 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476535
Principal investigator 1 ModernaTX, Inc. $1,642.50 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476747
Principal investigator 1 ModernaTX, Inc. $3,285.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477159
Principal investigator 1 ModernaTX, Inc. $5,748.75 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477469
Principal investigator 1 ModernaTX, Inc. $6,570.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477563
Principal investigator 1 ModernaTX, Inc. $6,570.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477567
Principal investigator 1 ModernaTX, Inc. $7,391.25 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477685
Principal investigator 1 ModernaTX, Inc. $9,855.00 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477857
Principal investigator 1 ModernaTX, Inc. $13,961.25 07/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478017
Principal investigator 1 Janssen Research & Development, LLC $20,794.00 07/22/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236145
Principal investigator 1 ModernaTX, Inc. $3,075.00 07/20/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475161
Principal investigator 1 ModernaTX, Inc. $7,140.00 07/20/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477645
Principal investigator 1 ModernaTX, Inc. $11,342.94 07/20/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477913
Principal investigator 1 Janssen Research & Development, LLC $96,570.00 07/05/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236142
Principal investigator 1 ModernaTX, Inc. $250.00 06/29/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475995
Principal investigator 1 ModernaTX, Inc. $6,360.00 06/29/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477523
Principal investigator 1 ModernaTX, Inc. $7,519.50 06/29/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477705
Principal investigator 1 ModernaTX, Inc. $11,945.22 06/22/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477953
Principal investigator 1 Janssen Research & Development, LLC $22,445.00 06/17/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236085
Principal investigator 1 Janssen Research & Development, LLC $22,445.00 06/17/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236135
Principal investigator 1 ModernaTX, Inc. $2,147.50 06/17/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476797
Principal investigator 1 ModernaTX, Inc. $103.50 06/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475783
Principal investigator 1 ModernaTX, Inc. $1,153.13 06/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476599
Principal investigator 1 ModernaTX, Inc. $6,202.13 06/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477513
Principal investigator 1 ModernaTX, Inc. $11,813.63 06/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477943
Principal investigator 1 ModernaTX, Inc. $19,350.23 06/10/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478093
Principal investigator 1 ModernaTX, Inc. $27,982.50 06/08/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475429
Principal investigator 1 ModernaTX, Inc. $48,694.75 06/08/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475537
Principal investigator 1 ModernaTX, Inc. $75,097.10 06/08/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475587
Principal investigator 1 ModernaTX, Inc. $77,192.70 06/08/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475601
Principal investigator 1 ModernaTX, Inc. $181,275.25 06/08/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475677
Principal investigator 1 Janssen Research & Development, LLC $56,340.00 06/06/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236081
Principal investigator 1 Janssen Research & Development, LLC $56,340.00 06/06/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236131
Principal investigator 1 ModernaTX, Inc. $373.50 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476101
Principal investigator 1 ModernaTX, Inc. $373.50 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476105
Principal investigator 1 ModernaTX, Inc. $1,467.00 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476689
Principal investigator 1 ModernaTX, Inc. $2,246.63 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476865
Principal investigator 1 ModernaTX, Inc. $2,246.63 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476871
Principal investigator 1 ModernaTX, Inc. $3,340.13 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477183
Principal investigator 1 ModernaTX, Inc. $3,764.25 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477227
Principal investigator 1 ModernaTX, Inc. $4,087.13 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477247
Principal investigator 1 ModernaTX, Inc. $4,866.75 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477363
Principal investigator 1 ModernaTX, Inc. $6,401.25 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477527
Principal investigator 1 ModernaTX, Inc. $7,050.38 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477635
Principal investigator 1 ModernaTX, Inc. $7,638.75 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477715
Principal investigator 1 ModernaTX, Inc. $10,550.25 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477883
Principal investigator 1 ModernaTX, Inc. $27,739.13 06/03/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478149
Principal investigator 1 Janssen Research & Development, LLC $34,036.00 06/01/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236077
Principal investigator 1 Janssen Research & Development, LLC $34,036.00 06/01/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236127
Principal investigator 1 ModernaTX, Inc. $6,855.00 06/01/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477607
Principal investigator 1 ModernaTX, Inc. $43,381.25 06/01/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478179
Principal investigator 1 ModernaTX, Inc. $149,668.75 06/01/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478213
Principal investigator 1 ModernaTX, Inc. $180.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475921
Principal investigator 1 ModernaTX, Inc. $180.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475925
Principal investigator 1 ModernaTX, Inc. $180.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475931
Principal investigator 1 ModernaTX, Inc. $180.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475935
Principal investigator 1 ModernaTX, Inc. $360.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476065
Principal investigator 1 ModernaTX, Inc. $360.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476071
Principal investigator 1 ModernaTX, Inc. $360.00 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476075
Principal investigator 1 ModernaTX, Inc. $770.63 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476215
Principal investigator 1 ModernaTX, Inc. $821.25 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476333
Principal investigator 1 ModernaTX, Inc. $821.25 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476339
Principal investigator 1 ModernaTX, Inc. $2,497.50 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476969
Principal investigator 1 ModernaTX, Inc. $2,497.50 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476973
Principal investigator 1 ModernaTX, Inc. $5,748.75 05/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477463
Principal investigator 1 ModernaTX, Inc. $180.00 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475939
Principal investigator 1 ModernaTX, Inc. $770.63 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476219
Principal investigator 1 ModernaTX, Inc. $821.25 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476329
Principal investigator 1 ModernaTX, Inc. $821.25 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476345
Principal investigator 1 ModernaTX, Inc. $1,137.50 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476545
Principal investigator 1 ModernaTX, Inc. $1,248.75 05/25/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476625
Principal investigator 1 Janssen Research & Development, LLC $31,041.00 05/20/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236089
Principal investigator 1 Janssen Research & Development, LLC $31,041.00 05/20/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236139
Principal investigator 1 ModernaTX, Inc. $812.50 05/06/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476289
Principal investigator 1 ModernaTX, Inc. $2,730.00 05/06/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477035
Principal investigator 1 ModernaTX, Inc. $747.00 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476199
Principal investigator 1 ModernaTX, Inc. $779.63 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476239
Principal investigator 1 ModernaTX, Inc. $2,246.63 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476831
Principal investigator 1 ModernaTX, Inc. $2,246.63 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476835
Principal investigator 1 ModernaTX, Inc. $2,246.63 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476841
Principal investigator 1 ModernaTX, Inc. $2,246.63 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476845
Principal investigator 1 ModernaTX, Inc. $3,340.13 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477179
Principal investigator 1 ModernaTX, Inc. $3,415.50 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477193
Principal investigator 1 ModernaTX, Inc. $4,493.25 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477311
Principal investigator 1 ModernaTX, Inc. $4,807.13 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477351
Principal investigator 1 ModernaTX, Inc. $5,586.75 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477439
Principal investigator 1 ModernaTX, Inc. $5,646.38 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477445
Principal investigator 1 ModernaTX, Inc. $5,897.25 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477473
Principal investigator 1 ModernaTX, Inc. $6,739.88 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477581
Principal investigator 1 ModernaTX, Inc. $6,739.88 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477587
Principal investigator 1 ModernaTX, Inc. $8,493.75 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477775
Principal investigator 1 ModernaTX, Inc. $14,655.48 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478031
Principal investigator 1 ModernaTX, Inc. $16,261.56 05/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478037
Principal investigator 1 ModernaTX, Inc. $7,380.00 05/02/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477675
Principal investigator 1 ModernaTX, Inc. $8,835.00 05/02/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477811
Principal investigator 1 ModernaTX, Inc. $32.50 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475713
Principal investigator 1 ModernaTX, Inc. $195.00 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475959
Principal investigator 1 ModernaTX, Inc. $1,332.50 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476649
Principal investigator 1 ModernaTX, Inc. $2,000.00 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476787
Principal investigator 1 ModernaTX, Inc. $11,200.00 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477909
Principal investigator 1 ModernaTX, Inc. $22,200.00 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478113
Principal investigator 1 ModernaTX, Inc. $30,600.00 04/27/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478158
Principal investigator 1 Janssen Research & Development, LLC $17,333.00 04/22/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236073
Principal investigator 1 Janssen Research & Development, LLC $17,333.00 04/22/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236123
Principal investigator 1 Janssen Research & Development, LLC $14,700.00 03/28/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236041
Principal investigator 1 Janssen Research & Development, LLC $84,315.00 03/23/2022 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885236037
Principal investigator 1 ModernaTX, Inc. $103.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475779
Principal investigator 1 ModernaTX, Inc. $1,093.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476479
Principal investigator 1 ModernaTX, Inc. $1,093.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476483
Principal investigator 1 ModernaTX, Inc. $1,093.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476487
Principal investigator 1 ModernaTX, Inc. $1,300.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476645
Principal investigator 1 ModernaTX, Inc. $2,187.00 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476805
Principal investigator 1 ModernaTX, Inc. $3,280.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477125
Principal investigator 1 ModernaTX, Inc. $3,280.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477129
Principal investigator 1 ModernaTX, Inc. $3,280.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477135
Principal investigator 1 ModernaTX, Inc. $3,280.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477139
Principal investigator 1 ModernaTX, Inc. $3,280.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477145
Principal investigator 1 ModernaTX, Inc. $3,829.50 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477233
Principal investigator 1 ModernaTX, Inc. $4,374.00 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477281
Principal investigator 1 ModernaTX, Inc. $4,374.00 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477287
Principal investigator 1 ModernaTX, Inc. $6,561.00 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477547
Principal investigator 1 ModernaTX, Inc. $13,122.00 03/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477991
Principal investigator 1 ModernaTX, Inc. $180.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475833
Principal investigator 1 ModernaTX, Inc. $180.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475839
Principal investigator 1 ModernaTX, Inc. $180.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475845
Principal investigator 1 ModernaTX, Inc. $360.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476021
Principal investigator 1 ModernaTX, Inc. $360.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476025
Principal investigator 1 ModernaTX, Inc. $360.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476031
Principal investigator 1 ModernaTX, Inc. $540.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476131
Principal investigator 1 ModernaTX, Inc. $540.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476135
Principal investigator 1 ModernaTX, Inc. $540.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476141
Principal investigator 1 ModernaTX, Inc. $540.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476145
Principal investigator 1 ModernaTX, Inc. $720.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476185
Principal investigator 1 ModernaTX, Inc. $770.63 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476209
Principal investigator 1 ModernaTX, Inc. $821.25 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476295
Principal investigator 1 ModernaTX, Inc. $821.25 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476299
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476413
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476419
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476423
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476429
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476433
Principal investigator 1 ModernaTX, Inc. $900.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476439
Principal investigator 1 ModernaTX, Inc. $1,260.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476639
Principal investigator 1 ModernaTX, Inc. $1,440.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476665
Principal investigator 1 ModernaTX, Inc. $1,440.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476669
Principal investigator 1 ModernaTX, Inc. $1,440.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476675
Principal investigator 1 ModernaTX, Inc. $1,541.25 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476713
Principal investigator 1 ModernaTX, Inc. $1,800.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476757
Principal investigator 1 ModernaTX, Inc. $1,800.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476763
Principal investigator 1 ModernaTX, Inc. $1,800.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476767
Principal investigator 1 ModernaTX, Inc. $2,463.75 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476923
Principal investigator 1 ModernaTX, Inc. $2,463.75 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476929
Principal investigator 1 ModernaTX, Inc. $2,497.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476963
Principal investigator 1 ModernaTX, Inc. $2,520.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476983
Principal investigator 1 ModernaTX, Inc. $2,700.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477031
Principal investigator 1 ModernaTX, Inc. $3,082.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477065
Principal investigator 1 ModernaTX, Inc. $3,240.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477109
Principal investigator 1 ModernaTX, Inc. $3,285.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477155
Principal investigator 1 ModernaTX, Inc. $3,600.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477207
Principal investigator 1 ModernaTX, Inc. $4,500.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477321
Principal investigator 1 ModernaTX, Inc. $4,500.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477327
Principal investigator 1 ModernaTX, Inc. $4,860.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477357
Principal investigator 1 ModernaTX, Inc. $4,927.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477373
Principal investigator 1 ModernaTX, Inc. $4,995.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477393
Principal investigator 1 ModernaTX, Inc. $4,995.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477399
Principal investigator 1 ModernaTX, Inc. $6,935.63 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477631
Principal investigator 1 ModernaTX, Inc. $7,380.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477670
Principal investigator 1 ModernaTX, Inc. $8,212.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477755
Principal investigator 1 ModernaTX, Inc. $8,280.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477761
Principal investigator 1 ModernaTX, Inc. $8,460.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477765
Principal investigator 1 ModernaTX, Inc. $8,741.25 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477797
Principal investigator 1 ModernaTX, Inc. $9,033.75 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477821
Principal investigator 1 ModernaTX, Inc. $10,515.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477879
Principal investigator 1 ModernaTX, Inc. $17,064.60 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478056
Principal investigator 1 ModernaTX, Inc. $17,482.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478065
Principal investigator 1 ModernaTX, Inc. $17,482.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478071
Principal investigator 1 ModernaTX, Inc. $18,888.75 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478089
Principal investigator 1 ModernaTX, Inc. $27,472.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478143
Principal investigator 1 ModernaTX, Inc. $29,565.00 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478153
Principal investigator 1 ModernaTX, Inc. $44,347.50 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478183
Principal investigator 1 ModernaTX, Inc. $54,714.38 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478189
Principal investigator 1 ModernaTX, Inc. $126,123.75 03/04/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478207
Principal investigator 1 ModernaTX, Inc. $103.50 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963475737
Principal investigator 1 ModernaTX, Inc. $779.63 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476235
Principal investigator 1 ModernaTX, Inc. $1,153.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476561
Principal investigator 1 ModernaTX, Inc. $1,153.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476565
Principal investigator 1 ModernaTX, Inc. $1,153.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476571
Principal investigator 1 ModernaTX, Inc. $1,153.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476575
Principal investigator 1 ModernaTX, Inc. $1,153.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476581
Principal investigator 1 ModernaTX, Inc. $2,306.25 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476905
Principal investigator 1 ModernaTX, Inc. $4,937.63 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477389
Principal investigator 1 ModernaTX, Inc. $9,802.13 02/23/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477843
Principal investigator 1 ModernaTX, Inc. $59,888.40 02/16/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475563
Principal investigator 1 ModernaTX, Inc. $84,603.35 02/16/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475621
Principal investigator 1 ModernaTX, Inc. $106,290.60 02/16/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 963475645
Principal investigator 1 ModernaTX, Inc. $9,495.00 02/11/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477832
Principal investigator 1 ModernaTX, Inc. $16,964.22 02/11/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963478051
Principal investigator 1 ModernaTX, Inc. $1,256.63 02/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476630
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963476695
Principal investigator 1 ModernaTX, Inc. $8,901.00 02/09/2022 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963477817